Moderna and Merck’s personalised mRNA vaccine met key goals in a Phase 3 melanoma trial, reducing recurrence and spread and raising hopes for a new generation of cancer vaccines worldwide
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.